With 30-year industry chops, Pamela Conley launches a protein therapeutics biotech for autoimmune diseases

After about 17 years at Portola Pharmaceuticals, Pamela Conley was ready for her next venture once helping transition some of the drugmaker’s programs into Alexion in mid-to-late 2020.

Since then, she’s been setting up shop at autoimmune-focused Nuvig Therapeutics, which broke cover Wednesday with $47 million from Novo Holdings, Platanus,...

Click to view original post